DRMA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Dermata Therapeutics Inc (DRMA) is not a good buy for a beginner, long-term investor at this time. The stock lacks positive catalysts, has weak financial performance, and no significant trading signals or trends to support a buy decision. The technical indicators suggest a bearish trend, and the company's financials show significant losses. Given the lack of news, analyst ratings, and congressional trading data, there are no strong reasons to invest in this stock currently.
The MACD is slightly positive, but the RSI is neutral, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with support at 1.116 and resistance at 1.36. Overall, the technical indicators do not suggest a strong buy opportunity.
NULL identified. No recent news or events to act as a positive catalyst.
Weak financial performance with significant YoY declines in net income (-46.68%) and EPS (-91.92%). No significant trading trends from hedge funds or insiders.
In Q3 2025, the company reported zero revenue growth (0.00% YoY), a net income loss of -$1,691,989 (-46.68% YoY), and a significant drop in EPS (-91.92% YoY). Gross margin remains at 0, indicating no profitability.
No analyst ratings or price target changes available for review.
